{"id":"placebo-to-baloxavir-marboxil","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL4297503","moleculeType":"Small molecule","molecularWeight":"571.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baloxavir marboxil is a prodrug that is converted to its active form, baloxavir, which selectively inhibits the influenza virus cap-dependent endonuclease (PA endonuclease). This enzyme is essential for the viral polymerase complex to cleave host pre-mRNA caps, which are then used to prime viral mRNA synthesis. By blocking this step, baloxavir prevents the generation of viral mRNA and halts influenza virus replication at an early stage of infection.","oneSentence":"Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus polymerase, preventing viral mRNA synthesis and replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:32.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute uncomplicated influenza (treatment)"},{"name":"Influenza prophylaxis (prevention)"}]},"trialDetails":[{"nctId":"NCT06507813","phase":"PHASE3","title":"Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza","status":"COMPLETED","sponsor":"Jiaxing AnDiCon Biotech Co.,Ltd","startDate":"2024-08-19","conditions":"Influenza Type A, Influenza Type B","enrollment":190},{"nctId":"NCT03969212","phase":"PHASE3","title":"Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-10-10","conditions":"Influenza","enrollment":4138},{"nctId":"NCT05170009","phase":"PHASE2, PHASE3","title":"Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2022-04-22","conditions":"Influenza","enrollment":2},{"nctId":"NCT06653569","phase":"PHASE3","title":"Efficacy of Baloxavir Against Influenza in Hospitalized Patients: the INFLUENT Study (INpatients InFLUENza Treatment)","status":"RECRUITING","sponsor":"Dre Pauline Vetter","startDate":"2024-12","conditions":"Influenza Disease; Flu","enrollment":484},{"nctId":"NCT03684044","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-08","conditions":"Influenza","enrollment":363},{"nctId":"NCT03629184","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-20","conditions":"Influenza","enrollment":173},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Baloxavir Marboxil","genericName":"Placebo to Baloxavir Marboxil","companyName":"Shionogi","companyId":"shionogi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus polymerase, preventing viral mRNA synthesis and replication. Used for Acute uncomplicated influenza (treatment), Influenza prophylaxis (prevention).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}